13 April 2021 
EMA/207785/2021  
Human Medicines Evaluation Division 
Statement indicating compliance with the agreed 
completed paediatric investigation plan 
Medicinal product  
Xarelto/Rivaroxaban 
See Annex A  
Pharmaceutical form(s): 
See Annex A 
Strength(s): 
Route(s) of administration: 
See Annex A 
Packaging and package size(s):  See Annex A 
See Annex A 
Number(s) in the Community 
Register of Medicinal Products: 
Marketing authorisation holder (MAH): 
Name and address of the MAH:  Bayer AG 
51368 Leverkusen 
Germany 
Procedure  
Procedure number: 
EMEA/H/C/000944/IB/0088 
Further to the compliance check performed under Article 23 of Regulation (EC) No 1901/2006, and in 
accordance with Article 28(3) and Article 45(3) of the said Regulation it is concluded that: 
The applicant has full compliance confirmed by PDCO. 
All the results of the PIP are already represented in the SmPC. 
In the paediatric line extension X-74-G the following PIP measures were presented and the 
assessment report concluded:  
- extension of indication to include treatment and prevention of venous thromboembolism in term 
neonates, infants and toddlers, children, and adolescents aged less than 18 years.  
The development of this product has complied with all measures in the agreed paediatric 
investigation plan P/0126/2019. All studies in the agreed paediatric investigation plan P/0126/2019 
were conducted after the entry into force of that Regulation. 
All conditions for the compliance statement are fulfilled. 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
